Loading...
XJPX
4559
Market cap538mUSD
Oct 09, Last price  
1,925.00JPY
1D
-0.21%
1Q
-7.45%
Jan 2017
6.71%
Name

Zeria Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XJPX:4559 chart
P/E
10.04
P/S
0.95
EPS
191.80
Div yield, %
2.49%
Shrs. gr., 5y
-0.88%
Rev. gr., 5y
11.06%
Revenues
89.16b
+2.12%
52,757,058,00049,721,899,00047,670,496,00050,745,707,00049,482,197,00053,169,587,00053,317,844,00061,996,830,00061,012,609,00062,475,030,00064,860,181,00064,577,699,00061,823,760,00060,435,230,00052,757,184,00059,532,829,00068,383,227,00075,725,075,00087,311,137,00089,159,262,000
Net income
8.45b
-14.91%
2,068,188,0001,639,098,0001,203,139,0001,001,776,0001,842,695,0002,861,017,0003,982,226,0005,277,080,0002,557,646,0003,513,496,0003,544,360,0004,157,810,0003,454,098,0002,925,375,0003,143,125,0003,961,185,0006,195,865,0007,731,261,0009,936,323,0008,454,543,000
CFO
9.96b
-22.96%
2,749,235,0003,759,286,000423,628,0005,858,132,0005,847,559,0006,028,426,0003,878,531,0006,573,328,000653,283,0005,694,606,0007,238,497,0008,821,935,0005,500,730,0007,251,345,0006,894,290,0008,950,932,00013,157,415,00012,183,609,00012,922,046,0009,955,621,000
Dividend
Mar 30, 202725 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.

Key people

Sachiaki Ibe
Chairman of the Board, Chief Executive Officer, Representative Director · since 2014
Mitsuhiro Ibe
President, Chief Operating Officer, Representative Director · since 2014
Hiroki Kato
Managing Executive Officer, Chief Director of Asia Business, Director of Asia Business Planning, Director of Asia Business Development · since 2022
Masakazu Sakurai
Managing Executive Officer, Chief Director of European Business, Director of European Business · since 2025
Kazuhiro Akiba
Executive Officer, Director of Pharmaceutical Sales · since 2022
Kenji Kusano
Executive Officer, Chief Director of Consumer Health Care Sales · since 2022
Yuuki Okazawa
Managing Executive Officer, Chief Director of Administration, Director of Human Resources, Director · since 2024
Yoshihiro Hiraga
Executive Officer, Chief Director of Research & Development · since 2022
Mitsuru Iwai
Executive Officer, Chief Director of Production & Logistics · since 2022
Toshiaki Kawagoe
Executive Officer, Chief Director of Reliability Assurance · since 2022
Kenichi Suzuki
Executive Officer, Senior Director of Corporate Planning, Director of Corporate Strategy Promotion · since 2022
Yasuhisa Tanaka
Executive Officer, Chief Director of Finance and Accounting, Director of Finance, Director of Accounting · since 2024
Takeshi Watanabe
Executive Officer, Manager of Central Research Institute · since 2025
Tetsuo Komori
Independent Director · since 2015
Seiji Morimoto
Independent Director · since 2020
Kikuo Nomoto
Independent Director · since 2017
IPO date
Dec 22, 1998
Employees
1,729
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT